Bank of America
RPRX icon

Bank of America’s Royalty Pharma RPRX Stock Holding History

Bank of America’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$233M Buy
4,149,422
+653,576
+19% +$34M 0.02% 721
2026
Q1 		$168M Buy
3,495,846
+786,921
+29% +$34.5M 0.01% 823
2025
Q4 		$105M Buy
2,708,925
+62,153
+2% +$2.37M 0.01% 1080
2025
Q3 		$93.4M Buy
2,646,772
+605,428
+30% +$21.9M 0.01% 1253
2025
Q2 		$73.5M Sell
2,041,344
-1,984,239
-49% -$65.7M 0.01% 1373
2025
Q1 		$125M Buy
4,025,583
+1,039,998
+35% +$33M 0.01% 953
2024
Q4 		$76.2M Buy
2,985,585
+950,880
+47% +$25.2M 0.01% 1217
2024
Q3 		$57.6M Buy
2,034,705
+16,110
+0.8% +$446K ﹤0.01% 1446
2024
Q2 		$53.2M Buy
2,018,595
+115,353
+6% +$3.2M ﹤0.01% 1408
2024
Q1 		$57.8M Buy
1,903,242
+559,256
+42% +$16.5M 0.01% 1374
2023
Q4 		$37.8M Sell
1,343,986
-151,288
-10% -$4.16M ﹤0.01% 1580
2023
Q3 		$40.6M Sell
1,495,274
-51,257
-3% -$1.52M ﹤0.01% 1412
2023
Q2 		$47.5M Sell
1,546,531
-335,879
-18% -$11.4M 0.01% 1346
2023
Q1 		$67.8M Buy
1,882,410
+558,884
+42% +$20.7M 0.01% 1165
2022
Q4 		$52.3M Sell
1,323,526
-176,020
-12% -$7.35M 0.01% 1273
2022
Q3 		$60.3M Sell
1,499,546
-139,381
-9% -$5.95M 0.01% 1134
2022
Q2 		$68.9M Sell
1,638,927
-321,601
-16% -$13.2M 0.01% 1082
2022
Q1 		$76.4M Buy
1,960,528
+89,239
+5% +$3.5M 0.01% 1102
2021
Q4 		$74.6M Sell
1,871,289
-18,362
-1% -$713K 0.01% 1145
2021
Q3 		$68.3M Buy
1,889,651
+297,095
+19% +$11.5M 0.01% 1168
2021
Q2 		$65.3M Buy
1,592,556
+166,677
+12% +$7.09M 0.01% 1193
2021
Q1 		$62.2M Buy
1,425,879
+983,540
+222% +$46.6M 0.01% 1149
2020
Q4 		$22.1M Buy
442,339
+283,341
+178% +$12M ﹤0.01% 1783
2020
Q3 		$6.69M Buy
158,998
+155,967
+5,146% +$6.69M ﹤0.01% 2632
2020
Q2 		$147K Buy
+3,031
New +$150K ﹤0.01% 5452

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America's RPRX Position: Q2 2026 in Review

Bank of America increased its Royalty Pharma (RPRX) stake by 19% in Q2 2026, buying an estimated $34M and bringing the position to 4,149,422 shares worth $233M. The position accounts for 0.02% of the portfolio, ranked #721.

Bank of America first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Bank of America held 4,149,422 shares of Royalty Pharma worth $233M as of Q2 2026.
  • Bank of America bought 653,576 Royalty Pharma shares in Q2 2026, an estimated $34M.
  • Royalty Pharma made up 0.02% of Bank of America's portfolio in Q2 2026, its #721 holding.
  • Bank of America first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.